Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: An update

Current Opinion in Hematology

Volumn 10, Issue 1, 2003, Pages 40-48

  Anastasiadou, Ema ^a,b   Schwaller, Juerg ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANSAMYCIN DERIVATIVE; CEP 701; CPG 57148; GELDANAMYCIN; HERBIMYCIN A; IMATINIB; INDOLOCARBAZOLE DERIVATIVE; MIDOSTAURIN; PIPERAZINYLQUINALIZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STAUROSPORINE; SU 11128; UNCLASSIFIED DRUG;

CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FUSION GENE; HUMAN; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES;

EID: 0037214279     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200301000-00007     Document Type: Review

References (70)

1. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Jena N, Deng M, Sicinska E, et al.: Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res 2002, 62:535-541. In this study, the authors have identified cyclin-D2 as target of BCR/ABL by using DNA microarray technology. Of interest is their finding that cells lacking one or both copies of the cyclin-D2 gene were resistant to BCR/ABL-induced proliferation. This finding suggests that a distinct threshold of cyclin-D2 activity may be necessary for BCR/ABL transformation
3. Deininger MW, Vieira SA, Parada Y, et al.: Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res 2001, 61:8005-8013.
4. Sonoyama J, Matsumura I, Ezoe S, et al.: Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002, 277:8076-8082.
5. Parada Y, Banerji L, Glassford J, et al.: BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27KIP1 expression. J Biol Chem 2001, 276:23572-23580.
6. Brennan P, Mehl AM, Jones M, et al.: Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002, 21:1263-1271.
7. KIP1. Mol Cell Biol 2000, 20:9138-9148.
8. Million RP, Van Etten RA: The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the BCR/ABL tyrosine kinase. Blood 2000, 96:664-670.
9. Sattler M, Mohi MG, Pride YB, et al.: Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002, 1:479-492. Using a genetic approach, this group of researchers demonstrate a critical role of the scaffold adapter molecule Gab2 in transformation of myeloid cells by the BCR/ABL fusion protein
10. Coller HA, Grandori C, Tamayo P, et al.: Expression analysis with oligonucleotide microarrays reveals that Myc regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000, 97:3260-3265.
11. Sicinski P, Donaher JL, Geng Y, et al.: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996, 6608:470-474.
12. Perrotti D, Cesi V, Trotta R, et al.: BCR-ABL suppresses C/EPBα expression through inhibitory action of hnRNP E2. Nat Genet 2002, 30:48-58.
13. Pabst T, Mueller B, Zhang P, et al.: Dominant-negative mutations of CEBP, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
14. Gombart A, Hoffman WK, Kawano S, et al.: Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemia. Blood 2002, 99:1332-1340.
15. Deutsch E, Dugray A, AbdulKarim B, et al.: BCR-ABL downregulates the DNA repair protein DNA-PKcs. Blood 2001, 97:2084-2090. This article demonstrates downregulation of the mammalian DNA repair protein DNA-PKcs by the BCR/ABL fusion protein. It suggests that deficiency of a major DNA repair protein in conjunction with resistance to apoptosis, both induced by BCR/ABL may provide a possible mechanism to explain accumulation of secondary genetic alterations that eventually lead to blast crisis
16. Van Gent DC, Hoeijmakers JH, Kanaar R: Chromosomal stability and the DNA double-stranded break connection. Nat Rev Gene 2001, 2:196-206.
17. Maru Y, Bergmann E, Coin F, et al.: TFIIH functions are altered by the p210BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat Res 2001, 483:83-88.
18. Slupinanek A, Schmutte C, Tombling G, et al.: BCR/ABL regulates mammalian RecA homologs, resulting by drug resistance. Mol Cell 2001, 8:795-806. This work, together with [19], demonstrates that BCR/ABL and other PTK fusion proteins associated with myeloproliferative disorders (TEL/ABL, TEL/JAK2, TEL/PDGFβR, TEL/TRKC) induce drug resistance by regulation of the RAD51 paralogues that play an important role in homologous recombination and repair of DNA double-strand breaks
19. Slupianek A, Hoser G, Majsterek I, et al.: Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol Cell Biol 2002, 22:4189-4201.
20. Hackett JA, Feldser DM, Greider CW: Telomere dysfunction increases mutation rate and genomic instability. Cell 2001, 106:275-286.
21. Hemann MT, Strong MA, Hao LY, et al.: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107:67-77.
22. Bruemmendorf TH, Holyoake TL, Rufer N, et al.: Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000, 95:1883-1890.
23. Boultwood J, Peniket A, Watkins F, et al.: Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000, 96:358-361.
24. Gilley D, Tanaka H, Hande MP, et al.: DNA-PKcs is critical for telomere capping. Proc Natl Acad Sci U S A 2001, 98:15084-15088.
25. Schwaller J, Anastasiadou E, Cain D, et al,: H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001, 97:3910-3918.
26. Kulkarni S, Heath C, Parker S, et al.: Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with t(5;10). Cancer Res 2000, 60:3592-3598.
27. Baxter EJ, Hochhaus A, Bolufer P, et al.: The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002, 11:1391-1397.
28. Nikiforova MN, Stringer JR, Blough R, et al.: Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000, 290:138-141.
29. Steer EJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta. Acta Haematol 2002, 107:113-122.
30. Kioyi H, Naoe T, Nakano Y, et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
31. Meshinchi S, Woods WG, Stirewalt DL, et al.: Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
32. Kottaridis PD, Gale RG, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML10 and 12 trials. Blood 2001, 98:1752-1759.
33. Whitman SP, Archer KJ, Feng L, et al.: Absence of wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 2001, 61:7233-7239.
34. Yamamoto Y, Kiyoi H, Nakano Y, et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
35. Kelly LM, Liu Q, Kutok JL, et al.: FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002, 99:310-318.
36. Naoe T, Kiyoi H, Yamamoto Y, et al.: FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother Pharmacol 2001, 48(suppl 1):S27-S30.
37. Boissan M, Feger F, Guillosson JJ, et al.: c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 2000, 67:135-148.
38. Longley BJ, Reguera MJ, Ma Y: Classes of c-kit activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001, 25:571-576.
39. Ma Y, Zeng S, Metcalfe DD, et al.: The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood 2002, 99:1741-1744.
40. Buchdunger E, Matter A, Druker BJ: Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001, 1551:M11-M18.
41. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
42. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
43. O'Dwyer ME, Mauro MJ, Druker BJ: Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002, 53:369-381.
44. Savage DG, Antman K: Imatinib mesylate: A new oral targeted therapy. N Engl J Med 2002, 346:683-693.
45. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BOR/ABL-transformed cell lines. Blood 2000, 95:3498-3505.
46. Mahon FX, Deininger MW, Schulteis B, et al.: Selection and characterization of BCR/ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanism of resistance. Blood 2000, 93:1070-1079.
47. Gambacorti-Passerini C, Barni R, Le Coutre P, et al.: Role of a1 acid glycoprotein in the in vivo resistance of human BCP/ABL+ leukemic cels to the Abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641-1650.
48. Jorgensen HG, Elliot MA, Allan EK, et al.: Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002, 99:713-715.
49. Gorre ME, Mansoor M, Ellwood K, et al.: Clinical resistance to imatinib mesylate cancer therapy caused by BCR-ABL gene mutation of amplification. Science 2001, 293:876-880. This report shows for the first time that acquired point mutations in the ATP-binding pocket of the BCR/ABL tyrosine kinase could underlie clinical resistance against the imatinib mesylate tyrosine kinase inhibitor in patients with CML
50. Barthe C, Cony-Makhoul P, Melo JV, et al.: Roots of clinical resistance to imatinib mesylate cancer therapy. Science 2001, 293:2163a.
51. Von Bubhoff N, Schneller F, Peschel C, et al.: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002, 359:487-491.
52. Hofmann WK, Jones LC, Lemp NA, et al.: Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99:1860-1862.
53. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al.: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000, 96:3195-3199.
54. Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic drugs. Blood 2001, 97:1999-2007.
55. Sunday X, Layton JE, Elefanty A, et al.: Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and ST571. Blood 2001, 97:2008-2015.
56. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7:228-234. This report presents an elegant molecular mechanism that may be applied to increase the efficacy of small molecule tyrosine kinase inhibitors. With the combination of imatinib mesylate (STI-571) to block tyrosine kinase activity and leptomycin B to block the nuclear export, the BCR/ABL fusion protein was trapped in the nucleus and led to apoptotic cell death
57. Kelly LM, Yu JC, Boulton CL, et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1:421-432. See [59•]
58. Weisberg E, Boulton C, Kelly LM, et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443. See [59•]
59. Levis M, Allebach J, Kam-Fai T, et al.: A FLT3 tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99:3885-3891. These three articles [57•-59•] demonstrate the in vitro and in vivo efficacy of new small molecule inhibitors (CT53518, PKC412, CEP701) targeting the FLT3 tyrosine kinase that is frequently constitutively activated by internal tandem duplication in patients with AML. This finding suggests that use of small tyrosine kinase inhibitors may not be limited to CML but may also be a promising for treatment for AML
60. Smolich BD, Yuen HA, West KA, et al.: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001, 97:1413-1423.
61. Mesters RM, Padro T, Bleker R, et al.: Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001, 98:241-243.
62. Shawver LK, Slamon D, Ullrich A: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
63. Blagosklonny MV: Hsp-90 associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 2002, 16:455-462.
64. Nimmanapalli R, O'Bryan E, Bhalla K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001, 61:1799-1804.
65. Citri A, Alroy I, Lavi S, et al.: Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J 2002, 21:2407-2417.
66. Kardinal C, Konkol B, Schultz A, et al.: Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 2000, 14:1529-1538.
67. Lim Y-M, Wong S, Lau G, et al.: BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc Natl Acad Sci U S A 2000, 97:12233-12238.
68. Agarwal N, Gerwitz A: Oligonucleotide therapeutics for hematologic disorders. Biochim Biophys Acta 1999, 1489:85-96.
69. Hammond SM, Caudy AA, Hannon GY: Post-transcriptional gene silencing by double stranded RNA. Nat Rev Genet 2001, 2:110-119.
70. Paddison PJ, Caudy AA, Bernstein E, et al.: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002, 16:948-958.